載入中
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
前收盤價
US$12.54
+US$0.12 · +0.97%
盤中時間採用ET。市場資料可能有所延遲。
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
日內區間
目前US$12.54
52週區間
目前US$12.54
盤中時間採用ET。市場資料可能有所延遲。
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
日內區間
目前US$12.54
52週區間
目前US$12.54
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1695.9萬 USD | 2022.2萬 USD | 1868.6萬 USD | 2649.6萬 USD | 2376.3萬 USD |
| 銷貨成本 | 1370.5萬 USD | 1758.8萬 USD | 1510.8萬 USD | 1333.1萬 USD | 1499.2萬 USD |
| 毛利 | 325.4萬 USD | 263.4萬 USD | 357.8萬 USD | 1316.5萬 USD | 877.1萬 USD |
| 研究與開發 | 1432萬 USD | 887.8萬 USD | 746.7萬 USD | 1018.1萬 USD | 1025.6萬 USD |
| 銷售、一般及管理費用 | 1392.5萬 USD | 1291萬 USD | 1137.7萬 USD | 1037.1萬 USD | 945.3萬 USD |
| 營業費用 | 2853.3萬 USD | 2201.6萬 USD | 1907.9萬 USD | 2082.6萬 USD | 1999.2萬 USD |
| 利息收入 | 185.9萬 USD | 204.8萬 USD | 234.1萬 USD | 27萬 USD | 1.1萬 USD |
| 利息支出 | 66.3萬 USD | 56.1萬 USD | 33.5萬 USD | 16.2萬 USD | 16.7萬 USD |
| 折舊和攤銷 | 186萬 USD | 148.3萬 USD | 130.3萬 USD | 127.2萬 USD | 123.8萬 USD |
| 營業利益 | −2527.9萬 USD | −1938.2萬 USD | −1550.1萬 USD | −766.1萬 USD | −1122.1萬 USD |
| 淨利 | −2387.9萬 USD | −3022.4萬 USD | −671.6萬 USD | −1959.9萬 USD | −1355.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM305.53萬0.00%787.4億 USD0.19%US$278.94+0.49%
ARK Israel Innovative Technology ETFIZRL182.22萬1.40%1.37億 USD0.49%US$28.36+1.61%
iShares Russell 2000 Growth ETFIWO112.73萬0.01%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO74.22萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC40.2萬0.03%13.17億 USD0.60%US$183+0.11%
iShares Russell 3000 ETFIWV16.62萬0.00%205.84億 USD0.20%US$440.97+0.63%
Vanguard Russell 2000 Growth ETFVTWG13.24萬0.01%17億 USD0.06%US$260.49+0.91%
Invesco NASDAQ Future Gen 200 ETFQQQS11.93萬0.52%2275.83萬 USD0.20%US$42.145+1.39%iShares Russell 2000 ETFIWMARK Israel Innovative Technology ETFIZRLiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 3000 ETFIWVVanguard Russell 2000 Growth ETFVTWGInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
